The human monoclonal antibody bexlotoxumab has been found effective for the prevention of recurrent Clostridium difficile infection among patients who are already receiving standard oral antibiotics for primary or recurrent infection. 2 double-blind, randomized controlled trails concluded that bexlotoxumab was more effective than placebo in the MODIFY I and MODIFY II studies, which involved 2,655 adults with C. difficile. Adding actoxumab, a second monoclonal antibody, to the bexlotoxumab regimen, however, did not improve its efficacy. Additional the findings:

• Prespecified subgroup analysis revealed that the recurrent infection rates were lower in the 2 groups receiving bexlotoxumab who were at high risk of recurrence or were more likely to develop an adverse reaction, when compared to placebo groups.
• The sustained cure rate, which was defined as initial clinical cure without recurrent infection by 12 weeks, were 64%, 58%, and 54%, respectively, for bexlotoxumab, bexlotoxumab plus actoxumab, and placebo groups.